Skip to main content

Pharmaceutical stocks had a rough year. Here's why 2020 could be better.

By Barron's  
   December 19, 2019

There’s a theme developing in the 2020 outlooks Wall Street analysts covering big pharma are putting out this week: next year is looking good for the sector. In a note out Wednesday morning, Morgan Stanley’s David Risinger upgraded his view on the industry to Attractive from In-Line.

Full story

Get the latest on healthcare leadership in your inbox.